Drugs & Targets Galen platform receives FDA Breakthrough Device Designation June 11, 2021Vol.47 No.23
Drugs & Targets BIG, EORTC, AFT collaborate with Sanofi to study amcenestrant in the adjuvant setting for estrogen receptor-positive breast cancer June 11, 2021Vol.47 No.23
Drugs & TargetsFree Truseltiq receives FDA accelerated approval for metastatic cholangiocarcinoma June 04, 2021Vol.47 No.22
Drugs & TargetsFree Lumakras receives FDA accelerated approval for KRAS G12C mutated NSCLC June 04, 2021Vol.47 No.22
Drugs & TargetsFree European Commission approves Opdivo + Yervoy as first-line treatment for unresectable malignant pleural mesothelioma June 04, 2021Vol.47 No.22
Drugs & TargetsFree Rybrevant receives FDA approval as first targeted therapy for subset of NSCLC May 28, 2021Vol.47 No.21
Drugs & TargetsFree Pylarify receives FDA approval as first and only commercially available PSMA PET imaging agent for prostate cancer May 28, 2021Vol.47 No.21
Drugs & TargetsFree Opdivo + Yervoy receives Positive CHMP Opinion for colorectal cancer May 28, 2021Vol.47 No.21
Drugs & TargetsFree Keytruda receives Positive EU CHMP Opinion in combination with chemotherapy as first-line treatment for certain patients with esophageal cancer or HER2- GEJ adenocarcinoma May 28, 2021Vol.47 No.21
